Investing in China's Pharmaceutical Industry - 2nd Edition

Investing in China’s Pharmaceutical Industry is the second edition of a paper published by PwC looking into the current pharmaceutical market conditions in China. The report covers various subjects that are considered to be of concern to the pharmaceutical industry and/or investors in the pharmaceutical (pharma) industry in China. This publication builds on the foundation set in the first report, published in 2006. The pharmaceutical/ life sciences landscape is changing fast in China and this new edition reviews, updates and expands on the following key areas: Traditional Chinese Medicine (TCM), China's OTC Market, Medical Devices, CROs and CMOs, Development of Innovation, Tax Incentives in China, Bribery & Corruption in Sales and Marketing, Challenge of Drug Pricing, Distribution Systems, Intellectual Property Protection, Market Consolidation and Financial Impacts of Investments.

Contact us

Mike Swanick
Global Pharma and Life Sciences Leader, PwC US
Tel: +1 (267) 330 6060

Douglas Strang
Global & US Pharma/LS Advisory Leader, PwC US
Tel: +1 (267) 330 3045

Andrew Packman
Global Pharma/LS Tax Leader, PwC UK
Tel: +44 (0)189 552 2104

Peter Kartscher
Global Pharma/LS Assurance Leaser, PwC Israel
Tel: +972 3 795 4410

Follow us